Areas where skin must constantly resist gravitational pull tend to show laxity earlier
Berenbaum, F., Bougault, C
B-12 INJECTIONS Looking for a simple way to boost your energy and improve your health
No.:GL-VL-0109 CAS CAS:N/A Formula:Lyophilized MW:Variable (polymeric) Batch No.:QC2026-VL0109-3065 Mfg Date:2026-02-11 Test Date:2026-02-15 Sample Wt.:34.0 mg Appearance:White lyophilized powder in sealed vials Storage:2-8C, protect from light Spec.: Q/SH-VL-2026 Analytical Method & Instrumentation Method:Reversed-Phase HPLC (USP , ChP 0512) Instrument:Agilent 1260 Infinity II HPLC System (SN: DE86952) Column:Agilent ZORBAX Eclipse Plus C18, 2504.6mm, 5m (Lot: B69255) A Mobile Phase A:0.1% Trifluoroacetic acid (TFA) in Milli-Q Water (18.2 Mcm) B Mobile Phase B:0.1% TFA in Acetonitrile (HPLC Grade, Fisher Scientific) Gradient:0min5%B, 5min20%B, 20min60%B, 28min95%B, 30min95%B / Flow/Temp:1.0 mL/min / 30.0 0.5C (thermostatted) Detection:UV-DAD at 220nm (bandwidth 4nm, ref 360nm) Injection:20 L, sample conc
[1] Cell Line:Cultured Sprague-Dawley rat Achilles tendon fibroblasts (passages 2-4) Concentration:0, 0.5, 1, 2 g/mL Incubation Time:24 h Result:Did not alter total FAK, paxillin, or PCNA protein levels
